Latest News


DALL-E-Patient-Journey.jpeg

June 27, 2024 0

For some patients, particularly those with rare diseases, determining the cause of their symptoms can be a years-long struggle. To help them find the right diagnosis, they need educational materials that can connect them to appropriate care and empower them to take control of their health.

Tara Sheehy, Director of Client Experience at Phreesia, explained those needs in a recent webinar hosted by Phreesia and The DHC Group. The industry has made great progress with patient communication and care accessibility, Sheehy said, but “There is still a huge unmet need in the market, especially with patients who have rare or complex conditions.” Indeed, approximately half of rare-disease patients wait at least a year for a definitive diagnosis, and 20% wait more than five years.

And often, even after patients have gone through a lengthy process to obtain a diagnosis, they encounter an entire new set of challenges with their treatment. For that reason, patients need quick access to accurate information that can address their concerns, reduce their anxiety about the direction of their care and foster their adherence to treatment.

As patients look for specialist care and information about their symptoms or condition, there’s an industry opportunity to provide support that can shorten their path to diagnosis. Some patients have rare diseases that their physician has never seen, making them particularly difficult to diagnose, said Anthony Scatamacchia, SVP, Innovation, Patient Services at EVERSANA. With those difficulties in mind, he believes it’s critical to equip patients with resources to advocate for themselves in addressing some of the challenges that tend to crop up early in the treatment journey.

Claudia Kanaszyc, Associate Director at Amgen, explained how her group supports patients on their journey from developing symptoms to receiving treatment by advising them to tell their doctor how their symptoms are affecting their lives. For example, if a patient says double vision is preventing them from working or driving, their doctor is more likely to understand the symptomatic effects of a disease or condition and the pressing need for treatment.

“We want to prevent the long-term damage that can’t be reversed, so we are always educating them on providing the whole picture, not just the one part,” Kanaszyc explained.

Octapharma, meanwhile, has built online hubs to support patient education. As Eric Marrero, the company’s Director, Brand Marketing and Communications, described, the hubs allow patients to connect to educational materials or to talk one-on-one with nurse educators or clinicians.

“Those two programs are built out of the insights we got from our patients and everyone who takes care of them,” Marrero said. “Each one of them has to know what it is that they have to do to move that pendulum forward.”

Those insights, which Octapharma developed through market research with patients and healthcare professionals, are particularly important at a time when companies are trying to provide tailored resources. As Sheehy put it, “Personalization is power” and a key component of campaigns that prompt patients to act.

“You really have to meet the patient where they are, understand their mindset and give them content that’s really going to resonate and trigger them to say, ‘I need to take control of my own outcome,’” Phreesia’s Sheehy said. She sees that activation as key to help patients move along their care journey, “Whether that’s to seek a diagnosis or treatment, or be adherent to their medication,” she said.

Marrero emphasized the need to continue to assess the impact of a program throughout the lifecycle of a product. The patient population and treatment landscape will evolve over time, and campaigns need to shift with them to stay relevant, he said. Scatamacchia framed the need to assess what is working as part of the successful execution of omnichannel campaigns.

“You have to make sure that you’re providing benefit to the patient, so that they are leveraging those support services, and that also means showing up in different channels,” Scatamacchia said. “That means finding the different ways to be able to engage with them and offer value that extends beyond just providing their copay.”

Nick Paul Taylor

AI-shutterstock_2269396449.jpg

January 29, 2024 0

Brace yourselves for another year of rapid evolution across the digital landscape. That’s the takeaway from talks with eight industry leaders, who see advances in artificial intelligence, personalized messaging and channel optimization shaping direct-to-consumer (DTC) communications in 2024.

Predictions about new and intensifying trends are an annual tradition, but the changes in store for 2024 look more significant than usual to experienced leaders who have seen and driven the transformation of healthcare over the past decade. In the Phreesia report, Industry voices: Trends to watch in 2024, Pallavi Garg, Head of Global Oncology Products and Pipeline Strategy at Takeda, says now is perhaps “one of the most exciting times to work in our industry.”

Indeed, Cassandra Sinclair, a senior health and wellness advertising executive and board advisor, foresees the intersection of science and personalized storytelling fundamentally changing how teams engage consumers, patients and caregivers in 2024.

Brands have the tools to deliver messages at every point in the healthcare journey, from screening through treatment. They also have the power to personalize those messages, particularly at the point of care. As Roz Silbershatz Tomás, who leads the Global Libtayo Core Brand Team at Regeneron, explains, the point of care provides more opportunities for personalization and specificity than other channels, making it a key enabler of tailored, one-to-one campaigns.

“Point of care is a critical space to give the patient precise education on their disease state, knowing that they’re sitting in the doctor’s office, potentially about to make a decision on their healthcare and treatment,” she says.

The proliferation of options and embrace of omnichannel is driving companies to look at the role of each channel “with much more scrutiny,” says Alison Tapia, Senior Director, Performance Marketing and Digital Innovation at Dermavant Sciences.

“Brands are asking more questions to understand whether their strategy is working,” Tapia says. “Some of these critical considerations include: Are we reaching the right people? Are we showing up with appropriate messaging for that channel? Is it impactful? And can we compliantly message in that channel?”

Arielle Chavkin, Group Director of Digital Partnerships at Initiative, anticipates that teams will expand their communication toolkits in greater recognition of the needs and priorities of various patient subpopulations. That awareness makes it important to “truly embrace and plan campaigns based on how the same disease can impact different communities,” Chavkin says.

Social media also can help reach specific communities, but success requires an understanding of the nuances of each platform. Juli LeDoux, Director, Marketing–Patient at ImmunoGen, uses TikTok as an example. “Elaborating on disease states relevant to younger audiences or disease states that might not be considered as highly emotional, such as neurology or dermatology, is key for reaching the largest audience” on the popular short-form video app, she says.

Longer-term trends are building beneath the fast, continual shifts in where people meet online and within the communities they are building. Those long-term trends indicate that patients are, in the words of Meredith Odell, Senior Marketing Director at AstraZeneca, “choosing to share more, learn more and to be their own advocate.”

Artificial intelligence (AI) cuts across all of these trends, and teams are assessing its potential to do more for them operationally, from reviewing content to conducting market research. Over the past year, access to AI tools has become more democratized, observes Alexandra Beneville, Vice President of Content Strategy at Phreesia, and with those tools now more widely available to teams, she foresees 2024 as the year of AI adoption and application.

Nick Paul Taylor

digital-disruption-shutterstock_1590208255.jpg

January 16, 2024 0

Digital disruption is forcing a reevaluation of how to connect with patients. Responding to a series of major events—from upheaval at Twitter to the phasing out of third-party cookies—brands are adopting nimbler, more data-driven models that empower them to quickly switch tactics as the operating environment changes and they learn which approaches work best.

Amy Patel, Phreesia’s Director of Analytics, discussed this transforming landscape on a Digital Pharma East 2023 panel that weighed the best ways to reach patients in a world that is “increasingly complex, ever-changing and full of more and more obstacles and challenges,” as she described it.

The phasing out of third-party cookies was a major panel focus. Deprived of a resource that has long been a cornerstone of online engagement, teams now are putting more emphasis on collecting first-party data with consent. Lisa Frankina, Director of Digital Marketing for VIVITROL® at Alkermes, explained how her company works to build trust so that patients feel comfortable sharing their data.

“You want to connect with your audience and emotionally connect with patients,” Frankina said. “What we try to do is amplify the patient voice with first-hand testimonials—a video of someone who has actually been in that position—so that the content is relatable in order to make that authentic connection.”

In the previous, cookie-enabled world, brands could put their materials in front of patients no matter where they were on the internet. Lacking that option today, Natalie Wills, Associate Director of Marketing at Blueprint Medicines, is rethinking how Blueprint can ensure that patients see its content. Some of the new questions her team is asking include: “Where are patients looking for information? Are there ways we can reach patients outside of relying on cookies and data? Where we can put articles out there in the world where patients can find us and come to us?” Wills said.

Brands need a range of ways to connect with patients—and be willing to activate, optimize and switch tactics mid-campaign, the panel agreed. Grace Rodriguez, Head of DTC Portfolio Marketing, iPVU at UCB, described how those necessities manifest at her company.

“Having that nimbleness to really ensure that we are optimizing our spend and reaching those patients, while getting all of the data that we can to really tell that story, is pretty much No. 1 for us,” Rodriguez said. “What are those KPIs per channel, per tactic, per partner? If we’re not delivering on that, then you optimize or you move on.”

The capacity to pivot quickly is reshaping the media-planning cycle, too. The panelists explained that they now continually monitor how different aspects of a campaign are performing and adjust their approach as necessary throughout the year.

“We’ve built more flexibility into our media plans this year than in any year I ever have worked in this space,” said Jack Vance, Managing Director of Data and Activation at SOLVE(D), An IPG Health Company. “Every one of these media plans has a bucket of dollars, and we say ‘We’re going to decide where these go later in the year; we’re going to pick whichever platforms are working really well.’ ”

As Vance explained, a wait-and-see spending model requires brands to frame their definition of success at the start of a campaign, measure how its results compare to that agreed-upon definition and take action if performance falls short of expectations.

 

Nick Paul Taylor

telehealth-medium-shutterstock_2139345379.jpg

September 28, 2023 0

The point of care has changed dramatically over the past few years, with virtual platforms emerging as a major forum for patient-provider interactions. And that means DTC campaigns need to change, too.

A Phreesia survey of almost 2,000 patients added to evidence that the pandemic has had lasting effects on telehealth usage. More than one-third of survey respondents reported having had a virtual visit with a doctor in the past six months, and 84% of patients said they were at least “somewhat likely” to have a telehealth appointment within the next 12 months.

Those findings suggest that campaigns that focus exclusively on physical doctors’ offices will fail to reach a sufficient audience. Liz Dexter, Vice President for Point of Care at Publicis Health Media, explains how these findings inform strategy.

“We’re always evolving our approach depending on where patients are receiving care,” Dexter says. “It’s really changed a lot in the past three years. As care evolves, we have to evolve. We need to follow trends to make sure we are integrating in appropriate places to reach patients where they are.”

The relocation of many patient-physician encounters from the physical to the virtual realm is leading brand teams to confront new questions. Opportunities to connect with patients through telemedicine platforms still remain limited, Dexter says, but as the technology continues to evolve, it’s important to keep thinking about how to most effectively use it.

And because telemedicine is employed in different ways depending on the care scenario, campaigns need to reflect those differences to achieve best results, Dexter says. That means taking a bespoke approach to each specific use case, something she thinks is especially important.

“Ultimately, we want to empower patients around their telemedicine appointments, providing the right message to the right person at the right time,” Dexter says. “We need to understand how patients and HCPs are actually using telemedicine in specific-use cases, and then provide them with messaging that’s valuable in that moment.”

Phreesia’s survey found that many patients are receptive to receiving resources before, during and after their telehealth appointments. When asked what resources they most wanted, 36% of patients expressed interest in receiving medication information relevant to their condition, as well as guidance on support programs for their health issues (26%) and doctor discussion guides (22%).

The ability to provide patients with such personalized resources as doctor discussion guides makes telehealth platforms highly attractive, but it’s vital that the resources they offer are actually useful to patients.

“We want to provide something of value in this dynamic,” Dexter says. “We don’t just want to have a promotional message wherever we can get one in. We want it to be thoughtful and meaningful, and helpful to both the HCP and patient.”

In that regard, virtual campaigns are much the same as in-office campaigns. The goal is still to motivate patients to discuss their symptoms and treatment options with their physician and empower them to have the conversations that can ultimately improve their health. Telehealth offers new opportunities to do just that, while delivering tailored messaging and achieving measurable outcomes.

Nick Paul Taylor

lung-and-stethoscope-COPD-shutterstock_2123591477-MEDIUM.jpg

September 13, 2023 0

Chronic lower respiratory diseases are the sixth leading cause of death in the U.S., making them more deadly than conditions such as Alzheimer’s disease and diabetes.1 The good news is that there are several medications available to treat this group of illnesses, which include chronic obstructive pulmonary disease (COPD), and improve these individuals’ quality of life. But many patients aren’t having the conversations necessary to make that happen.

COPD patients’ symptoms include cough and shortness of breath.2 However, COPD manifests differently from patient to patient and sometimes develops very slowly. The lack of a clear signal that something is wrong means people need prompting to talk to their doctor about their breathing problems.

“Many people don’t even know they have COPD. They experience symptoms that they consider part of normal life progression and essentially learn to live with them,” says Norbert Feigler, MD, Senior Medical Director, Respiratory at AstraZeneca. “Estimates [suggest] as many as half of American COPD patients [are] not yet diagnosed.”

As COPD progresses, daily activities become more difficult, but the process is gradual. An individual may start to walk more slowly or avoid going up steps, incrementally—and often imperceptibly—adapting their lives so that they don’t get out of breath. When their physician asks how they’re doing, they may say they are fine, minimizing their experiences because they have adapted to an undiagnosed illness

That scenario creates an ideal opportunity for direct-to-consumer messaging, particularly at the point of care. If campaigns can help patients recognize that their symptoms and subtle lifestyle changes may be signs of a lung disease, they can encourage conversations between patients and their doctors that may lead to more timely treatment. And, since COPD-related lung damage is permanent, cutting the time to diagnosis can only improve outcomes.

“It can be particularly mentally and emotionally tolling when a patient is first diagnosed, knowing the damage to their lungs is irreversible,” Dr. Feigler says. “This is why it’s important for patients to recognize the signs and symptoms of COPD, driving earlier diagnosis, and ultimately allowing physicians to employ a more proactive approach to disease management.”

Point-of-care campaigns can play a vital role in minimizing that damage, as well as its psychological toll, by encouraging patients to talk to their physician when they first notice possible signs of COPD. Such campaigns can help those who are already diagnosed, too. A Phreesia survey of 1,994 COPD patients found that fewer than half (44%) of diagnosed COPD patients had had detailed discussions with their doctor about their breathing symptoms. In a potentially related finding, 34% of respondents said they lacked a full understanding of their condition.

Those results suggest that COPD patients may be missing out on treatments and lifestyle changes that could improve their quality of life and health outcomes. Albert Rizzo, MD, FACP, Chief Medical Officer at the American Lung Association, explains how educational campaigns can benefit COPD patients.

“One of the best things to help a COPD patient is to educate them about the importance of staying active” Dr. Rizzo says. “You don’t have to do 30 minutes on a treadmill every day, but walking to the mailbox, doing the steps once or twice a day, just trying to maintain a level of activity, can go a long way in helping them feel like they have better control in their day-to-day activities.”

An estimated 12.2 million Americans have been diagnosed with COPD, but even more are living with the disease without a diagnosis. Those numbers indicate that DTC campaigns that change the awareness and behaviors of even a fraction of those suffering with COPD can have a huge impact and address a great unmet need by encouraging patients and providers to work together to identify symptoms, diagnose COPD earlier and ultimately shift the standard of care to a proactive approach to disease management.

References

  1. “Leading Causes of Death,” National Center for Health Statistics, Centers for Disease Control and Prevention, Jan. 18, 2023.
  2. Lee, Y.-C., Chang, K.-Y. & Sethi, S. Association of Chronic Lower Respiratory Disease With County Health Disparities in New York State. JAMA Netw Open.2021;4(11):e2134268. doi:10.1001/jamanetworkopen.2021.34268

Nick Paul Taylor

Cancer-Patient-shutterstock_645685942-1200x797.jpg

March 10, 2023 0

Clearly understanding their diagnosis and treatment plan is vital for cancer patients in order for them to have an optimal treatment experience. In fact, studies have linked patient education to reduced depression and side effects from cancer therapies. Yet new data shows there are critical gaps in cancer patients’ knowledge about their condition and treatment.

Results from 825 patients diagnosed with or treated for cancer who were surveyed on Phreesia’s PatientInsights platform as they checked in for their doctors’ appointments revealed the breadth of that knowledge gap: More than one-third (34%) of surveyed patients were unaware of how advanced their cancer was.

That’s a percentage that Justin Holko, Vice President and head of the Global Oncology/Hematology Commercial Business Unit at Regeneron, finds troubling. Shubh Goel, Vice President and U.S. franchise head for Immuno-oncology and Gastrointestinal Tumors at AstraZeneca, shares his concerns, calling the statistic “a challenge for our industry to do better.”

Other survey findings further reinforced the conclusion that too many cancer patients are in the dark about important aspects of their condition and treatment. More than one-third (34%) of survey respondents said they lacked a clear understanding of their cancer therapy before starting treatment, while 17% understood their treatment “somewhat,” and a further 17% had little to no understanding of their treatment.

Similarly, only 35% of patients said they had undergone genetic or biomarker testing for their cancer, and 24% were unsure whether or not they had received such testing. The remaining 41% of surveyed patients did not undergo genetic or biomarker testing, depriving them and their physicians of insights that could have informed their care.

Holko sees those findings as evidence of the need for medical, commercial and research and development teams to make sure that every patient, caregiver, nurse and doctor has the opportunity to learn about all of the options available to them. But providing that education, particularly to patients, requires thoughtfulness: When communicating with patients at vulnerable points in their cancer journey, how information is conveyed is just as important as the knowledge itself.

“It’s not just your delivery of the education and facts, but doing it in a way that is uncomplicated, easy to understand, not overwhelming and that makes people feel like they’re equipped with the tools they need to go talk to their doctor or better understand their condition,” Holko explains. “It has to be done in a very personal way.”

Cancer-therapy drugmakers also play an important role in helping patients understand their diagnosis and treatment pathways. “Because we develop and make these cancer treatments, we have the opportunity to be an ally and an educator,” Goel says, highlighting the need “to work hand-in-hand with advocacy partners to advance dialogue with patients and grow our education efforts.”

Additional survey results indicated avenues for activating patients and improving their understanding of their cancer and available therapies. A majority (69%) of surveyed patients said they had sought resources beyond their healthcare provider to learn more about their illness. Online searches (48%), general cancer websites (36%) and specific cancer websites (32%) were cited as the most widely accessed resources.

Meeting patients where they are can better address their knowledge gaps and ultimately improve their cancer treatment, Holko says, pointing to the need for market research that can shed more light on how different patients find and absorb cancer information.

“It really comes down to understanding who your patients are and using every channel available to you to reach the right patient at the right time in a very personalized way,” he says.

 

Nick Paul Taylor